Results 191 to 200 of about 12,926,306 (256)
In vitro characterization of a bispecific anti-(PD-1/CTLA-4) single-chain diabody for cancer immunotherapy. [PDF]
Ghoreishi M +3 more
europepmc +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela +6 more
wiley +1 more source
Abstract Background/Aim Antiresorptive therapy represents a cornerstone in the management of osteoporosis and cancer‐related bone disease through suppression of osteoclast‐mediated bone resorption. As implant therapy becomes more common in aging populations, clinicians increasingly encounter patients receiving these medications, thus making their ...
Emilio A. Cafferata +2 more
wiley +1 more source
Life-threatening anaphylactic shock induced by cadonilimab (AK104), a PD-1/CTLA-4 bispecific antibody: a case report. [PDF]
Zheng Z, Li J, Huang Q.
europepmc +1 more source
Assessment of Clinical and Immunological Factors of Local Recurrence in Canine Soft Tissue Sarcoma
ABSTRACT Canine soft tissue sarcomas (STSs) are locally invasive tumours, making local recurrence a major clinical challenge. Time to recurrence (TTR) and associated immune factors remain poorly characterized. This study aimed to characterize the immune microenvironment of canine STS and identify factors associated with TTR.
Kazuki Mizuta +2 more
wiley +1 more source
Immune dysregulation from a novel CTLA-4 haploinsufficiency variant. [PDF]
Brodsky NN +9 more
europepmc +1 more source
Histiocytes: Multifaceted Regulators of Health and Disease
ABSTRACT The mononuclear phagocyte system encompasses macrophages, dendritic cells (DCs), and monocytes. Tissue‐resident macrophages and dendritic cells arise during embryogenesis and are replenished either through self‐renewal or by monocytes during inflammation.
Erika J. Gruber
wiley +1 more source
Immune checkpoint crosstalk: CTLA-4/CD80 engagement as a predictor of anti-PD-1/PD-L1 therapy outcome in NSCLC. [PDF]
Gumuzio J +10 more
europepmc +1 more source
The role of extracellular vesicles in cell–cell crosstalk in cardiotoxicity
Abstract figure legend Administration of a pharmacological agent can result in off‐target cardiotoxicity which can be driven by cell–cell crosstalk between healthy and dysfunctional cardiac cells. Extracellular vesicles (EVs) are lipid bilayer structures that can move biological cargo between cells, facilitating cell–cell crosstalk.
Gabriella Bachynskyj‐Bilas +5 more
wiley +1 more source

